title: Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer.
abstract: Fortunately, novel agents are nowadays available for the management of patients with castration-resistant prostate cancer (CRPC). Denosumab is a new bone-protective agent, approved for the prevention and management of skeletal-related events. Studies have demonstrated that denosumab has better efficacy and similar rate of adverse effects in comparison with zoledronic acid, which was the standard bone-protective agent. In the present review we study the cost-effectiveness of denosumab in patients with CRPC.
authors.affiliation: a 1st University Department of Urology , University of Athens, Aretaion Hospital , Athens , Greece.
authors.forename: Athanasios
authors.initials: A
authors.lastname: Dellis
authors.affiliation: b 2nd Univeristy Deparment of Urology , University of Athens, Sismanoglio General Hospital , Athens , Greece.
authors.forename: Athanasios
authors.initials: A
authors.lastname: Papatsoris
mesh_terms: D050071:Bone Density Conservation Agents / Q000191:economics / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000517:prevention & control* / Q000556:secondary; D003362:Cost-Benefit Analysis; D000069448:Denosumab / Q000191:economics / Q000627:therapeutic use*; D004164:Diphosphonates / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000191:economics / Q000627:therapeutic use; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000473:pathology*; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000069448:Denosumab; D000077211:Zoledronic Acid
keywords: Denosumab; castration-resistant; cost–effectiveness; economics; prostate cancer; skeletal-related events